Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
Episode 29 with Dr. Monica Carson on MS research funding
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Keystone Symposium: Innate Immunity and Determinants of Microbial Pathogenesis - joint with - Mechanisms of Pro-Inflammatory Diseases
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
Multiple sclerosis prevalence in the United States commercially insured population.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Dimethylfumarate Impairs Neutrophil Functions.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.
Novel MS Drugs Advance
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Pages
« first
‹ previous
…
60
61
62
63
64
65
66
67
68
…
next ›
last »